Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F.
Shaw, A.T., Friboulet, L., Leshchiner, I., Gainor, J.F., Bergqvist, S., Brooun, A., Burke, B.J., Deng, Y., Liu, W., Dardaei, L., Frias, R.L., Schultz, K.R., Logan, J., James, L.P., Smeal, T., Timofeevski, S., Katayama, R., Iafrate, A.J., Le, L., Mctigue, M., Getz, G., Johnson, T.W., Engelman, J.A.(2016) N Engl J Med 374: 54
- PubMed: 26698910 
- DOI: https://doi.org/10.1056/NEJMoa1508887
- Primary Citation of Related Structures:  
5A9U, 5AA8, 5AA9, 5AAA, 5AAB, 5AAC - PubMed Abstract: 
In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y) ...